Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.
As the AI infrastructure race accelerates, Nvidia's relentless innovation cycle and commanding market position point to sustained growth, with data center spending projected to reach trillions annually by 2030.
As global markets navigate a period of uncertainty, a select group of technology companies across Norway, Sweden, and Israel are posting explosive growth. We examine the financials and strategies behind Appear ASA, Hacksaw AB, and NextVision Stabilized Systems—firms turning innovation into investor returns.
As the EU's landmark 'Next Generation' fund nears its final payout deadlines, its ambitious goal of modernizing the bloc's economy is being hampered by bureaucracy, skills gaps, and questions over long-term sustainability, despite pockets of innovation.
Tripadvisor and Best Western's new AI-driven travel platform for the 2026 FIFA World Cup showcases the company's potential in high-stakes tourism. Yet, for investors, the real test remains translating innovation into sustained growth and market-beating returns.
Glaukos shares have rebounded nearly 8% in a month, yet remain down sharply over the past year. A deep dive into the numbers reveals a stark contrast: a discounted cash flow model suggests significant upside, while price-to-sales metrics paint a picture of a richly valued stock. Investors are left weighing the promise of future glaucoma innovation against current market multiples.
Samsung Electronics has launched a special edition Galaxy Z Flip7 for the 2026 Winter Olympics, packed with AI-powered translation and athlete-centric features, while also previewing new on-screen privacy controls designed to thwart 'shoulder surfing'. These dual announcements underscore the tech giant's push to blend high-profile partnerships with user-centric innovation as it seeks to differentiate in a competitive market.
The healthcare behemoth's robust 2025 results and 2026 guidance signal a landmark year ahead, as it navigates patent expirations and pricing pressures while maintaining its coveted dividend king status.
Despite a robust drug pipeline and steady long-term gains, AstraZeneca's recent share price stagnation has investors questioning its true worth. A deep dive into valuation models suggests the pharmaceutical giant may be trading at a significant discount to its intrinsic value, even as its P/E ratio appears elevated compared to peers.
Fueled by AI-driven ad innovations and surging social media engagement, Meta's advertising revenue is on track to surpass Google Search in 2024, marking a historic shift in the digital landscape.
Standex International's fiscal Q2 results showcase robust organic growth and record order intake, driven by a multi-year strategic pivot towards new product innovation and high-growth markets like grid infrastructure and defense.
Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.
The FDA clearance of Spectrum Dynamics' Veritas.AI platform marks a significant step forward for nuclear imaging, promising to cut scan times in half and enhance image clarity for critical applications like cancer theranostics.
Eli Lilly bolsters its long-term growth strategy through two new R&D partnerships and a key regulatory milestone for an ovarian cancer drug, signaling a strategic push beyond its blockbuster diabetes and obesity treatments.
As Eli Lilly prepares to report its Q4 and full-year 2025 results on February 4th, investors are weighing whether the pharmaceutical giant's premium valuation leaves room for a positive surprise, or if the stock is priced for perfection.
Amid market volatility, these three companies offering yields above 4% present a compelling case for income-focused investors, backed by strategic pivots and resilient business models.
Senator James Lankford's annual oversight report details what he calls wasteful federal spending, including controversial NIH-funded projects on transgender-related animal testing and aborted fetal tissue research, reigniting debates on scientific priorities and fiscal responsibility.
As crypto prediction markets surge past $6B in weekly volume, a new phase of growth beckons. Driven by institutional interest, regulatory evolution, and AI integration, these platforms are poised to redefine speculative finance.
With one in twelve salaried employees having worked in multiple countries, Colgate-Palmolive is leveraging international assignments as a core strategy to build agile, globally-minded leadership.
Albertsons' retail media division opens its first NYC office and unveils a new logo, signaling a significant expansion and strategic push to deepen ties with advertisers and agencies in the competitive retail media landscape.
